Lv YQ, Yuan L, Sun Y, Dou HW, Su JH, Hou ZP, et al
These compounds are classified as sulfonylureas or non-sulfonylureas (glinides) (Tan and Nelson, 1996)
The FDA-approved labels for GLP-1 receptor agonistsincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and exenatide (Byetta, Bydureon)specify refrigeration as the primary storage method for unopened pens or vials
Gastrointestinal Side Effects - Nausea, vomiting, diarrhea, and abdominal pain are common
This means that 67 people with (severe) cardiovascular risk need to be on Wegovy consistently to avoid one cardiovascular event, for example, a heart attack
Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition